UPC APP 9038/2025

—·EP2501384: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Streithilfe
Parteien: Kläger
Zentiva, k.s.
ZENTIVA PORTUGAL, LDA
Vertreter: Marc Lauzeral
Beklagte
Accord Healthcare B.V.
Accord Healthcare S.L.U.
ACCORD HEALTHCARE LIMITED
Novartis AG
Vertreter: Gregory Bacon (Bristows (Ireland) LLP); Rutger Kleemans (Freshfields); Daniela Ampollin (Trevisan & Cuonzo); Allard van Duijn (Freshfields)
Division: Milan CD
Richter: —
Technology: Organic Chemistry
Sprache: —
Erste Entscheidung: 21. März 2025

Entscheidungen

2025-03-21
AbgewiesenApplication Rop313
The Milan Central Division dismissed Zentiva K.S. and Zentiva Portugal's application to intervene under Rule 313 RoP in infringement proceedings between Accord Healthcare and Novartis concerning EP 2 501 384. The court held that parallelism between cases or the potential impact of one judgment on another does not establish the legal interest required for intervention, and that the intervening party's requested remedies must be non-contradictory to those of the supported party.
Rechtsfragen:Third party intervention under Rule 313 RoPLegal interest in interventionRes judicata and inter partes effects of UPC judgmentsArt. 33 UPCA case connections and bifurcation

Dokumente

7D549992AE02D0300AB0E8A7DA23ACE5_en.pdf2025-03-21ENGLISH